ストックスクリーナーアプリを入手
0.2857
1.72%
-0.005
アフターアワーズ：
.28
-0.0057
-2.00%
Allakos Inc (ALLK) 最新ニュース
Lee joins Lycia as CMO - BioCentury
It is Poised to be a Bull Market for Allakos Inc (ALLK) - SETE News
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - EIN News
Introducing Our Rant Against Allakos Inc - US Post News
FY2024 EPS Estimates for Allakos Lowered by Leerink Partnrs - Defense World
Allakos Inc [ALLK] Officer makes an insider purchase of 21,116 shares worth 23219.0. - Knox Daily
This Week’s 14.26% Gain In Allakos Inc (NASDAQ: ALLK) Taught Us Something New - Marketing Sentinel
Evaluating Allakos: Strategic Review, NOL Potential, and Kevin Tang's Activist Stake Amidst Biopharma Challenges - Smartkarma
What To Expect From Eli Lilly’s (LLY) Q4 Earnings - The Globe and Mail
Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR
Such Is The Power Of Allakos Inc (NASDAQ: ALLK) - Stocks Register
Allakos Inc: -85.21% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
Allakos stock tanks after company announces mass layoffs - MSN
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Allakos Inc - GuruFocus.com
The time has not yet come to remove your chips from the table: Allakos Inc (ALLK) - SETE News
Allakos stock plunges to 52-week low of $0.23 amid steep annual decline - Investing.com
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga
Allakos stock tumbles following AK006 trial discontinuation - MSN
Bay Area biotech firm guts staff, shuts trial after dangerous side effects - SFGATE
Allakos plunges 75% on phase 1 data for urticaria asset - MSN
Allakos (NASDAQ:ALLK) Cut to Hold at Citizens Jmp - Defense World
Allakos (NASDAQ:ALLK) Cut to Hold at Piper Sandler - Defense World
Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade - MSN
BioAge drops obesity drug; Akero, 89bio cash in on MASH data - BioPharma Dive
Allakos to cease AK006 development after trial setback - MSN
Allakos cuts 75% of workforce after chronic hives trial failure - Clinical Trials Arena
Bay Area biotech firm Allakos suddenly on brink of collapse after trial flops - MSN
Allakos stock hits 52-week low at $0.3 amid market challenges - Investing.com Canada
Allakos shares fall as Jefferies cuts price target to $0.40 By Investing.com - Investing.com Nigeria
Allakos decimated as Phase I Trial of AK006 fails - The Pharma Letter
Allakos shares fall as Jefferies cuts price target to $0.40 - MSN
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds - The Business Journals
Bay Area biotech firm suddenly on brink of collapse after trial flops - SFGATE
Allakos Restructures Amid AK006 Program Discontinuation - TipRanks
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Benzinga
Stock market news: Planet Image International surged by 160.47% while Allakos is still declining by 80.30% during mid day trading - Business Upturn
Allakos Inc. (ALLK) PT Lowered to $0.40 at Jefferies - StreetInsider.com
Dow Edges Higher; AT&T Posts Upbeat Earnings - Benzinga
Allakos Shares Plummet to All-Time Low After Lead Candidate Failure - MarketWatch
Stock market today: Allakos dropped by 76.37% whereas Onconetix jumped by 77.10% in early trading - Business Upturn
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Benzinga
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):